Literature DB >> 17301082

Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.

A Krarup-Hansen1, S Helweg-Larsen, H Schmalbruch, M Rørth, C Krarup.   

Abstract

Although it is well known that cisplatin causes a sensory neuropathy, the primary site of involvement is not established. The clinical symptoms localized in a stocking-glove distribution may be explained by a length dependent neuronopathy or by a distal axonopathy. To study whether the whole neuron or the distal axon was primarily affected, we have carried out serial clinical and electrophysiological studies in 16 males with testicular cancer before or early and late during and after treatment with cisplatin, etoposide and bleomycin at limited (<400 mg/m2 cisplatin), conventional (approximately 400 mg/m2 cisplatin) or high (>400 mg/m2 cisplatin) doses. At cumulative doses of cisplatin higher than 300 mg/m2 the patients lost distal tendon and H-reflexes and displayed reduced vibration sense in the feet and the fingers. The amplitudes of sensory nerve action potentials (SNAP) from the fingers innervated by the median nerve and the dorsolateral side of the foot innervated by the sural nerve were 50-60% reduced, whereas no definite changes occurred at lower doses. The SNAP conduction velocities were reduced by 10-15% at cumulative doses of 400-700 mg/m2 consistent with loss of large myelinated fibres. SNAPs from primarily Pacinian corpuscles in digit 3 and the dorsolateral side of the foot evoked by a tactile probe showed similar changes to those observed in SNAPs evoked by electrical stimulation. At these doses, somatosensory evoked potentials (SEPs) from the tibial nerve had increased latencies of peripheral, spinal and central responses suggesting loss of central processes of large dorsal root ganglion cells. Motor conduction studies, autonomic function and warm and cold temperature sensation remained unchanged at all doses of cisplatin treatment. The results of these studies are consistent with degeneration of large sensory neurons whereas there was no evidence of distal axonal degeneration even at the lowest toxic doses of cisplatin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301082     DOI: 10.1093/brain/awl356

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  41 in total

1.  Cisplatin induced sensory neuropathy is prevented by vascular endothelial growth factor-A.

Authors:  Samanta Vencappa; Lucy F Donaldson; Richard P Hulse
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  Non-cytotoxic Concentration of Cisplatin Decreases Neuroplasticity-Related Proteins and Neurite Outgrowth Without Affecting the Expression of NGF in PC12 Cells.

Authors:  Rafaela Scalco Ferreira; Neife Aparecida Guinaim Dos Santos; Nádia Maria Martins; Laís Silva Fernandes; Antonio Cardozo Dos Santos
Journal:  Neurochem Res       Date:  2016-07-29       Impact factor: 3.996

Review 3.  Sensory Neuronopathies.

Authors:  Allison Crowell; Kelly G Gwathmey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-23       Impact factor: 5.081

Review 4.  Autonomic nervous system and cancer.

Authors:  Marta Simó; Xavier Navarro; Victor J Yuste; Jordi Bruna
Journal:  Clin Auton Res       Date:  2018-03-28       Impact factor: 4.435

5.  Naringin Abrogates Cisplatin-Induced Cognitive Deficits and Cholinergic Dysfunction Through the Down-Regulation of AChE Expression and iNOS Signaling Pathways in Hippocampus of Aged Rats.

Authors:  Yassine Chtourou; Brahim Gargouri; Mohammed Kebieche; Hamadi Fetoui
Journal:  J Mol Neurosci       Date:  2015-04-21       Impact factor: 3.444

Review 6.  Platinum-induced peripheral neurotoxicity: From pathogenesis to treatment.

Authors:  Nathan P Staff; Guido Cavaletti; Badrul Islam; Maryam Lustberg; Dimitri Psimaras; Stefano Tamburin
Journal:  J Peripher Nerv Syst       Date:  2019-10       Impact factor: 3.494

7.  Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept.

Authors:  Hue Jung Park; Jennifer A Stokes; Elaine Pirie; James Skahen; Yuri Shtaerman; Tony L Yaksh
Journal:  Anesth Analg       Date:  2012-12-07       Impact factor: 5.108

8.  Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue.

Authors:  Virginia Ip; Johnson J Liu; Julian F B Mercer; Mark J McKeage
Journal:  Mol Pain       Date:  2010-09-13       Impact factor: 3.395

9.  Changes in laryngeal sensation evaluated with a new method before and after radiotherapy.

Authors:  Kikuko Ozawa; Yasushi Fujimoto; Tsutomu Nakashima
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-08-25       Impact factor: 2.503

10.  The pattern and diagnostic criteria of sensory neuronopathy: a case-control study.

Authors:  Jean-Philippe Camdessanché; Guillemette Jousserand; Karine Ferraud; Christophe Vial; Philippe Petiot; Jérôme Honnorat; Jean-Christophe Antoine
Journal:  Brain       Date:  2009-06-08       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.